LAUSR

Introduction The inflammation syndrome is typical for chronic kidney disease (CKD) and increases with the progression of CKD. It is extremely important to monitor the markers of inflammation in patients with CKD, as there is a clear relationship between the level of inflammation and mortality in these patients. Currently, there is no single approach to the treatment of chronic inflammation in patients with CKD. Methods This was a prospective open cohort study. We studied 31 patients on hemodialysis from March 1, 2020, to August 1, 2021, in 2 Moscow clinics (No. 7 and S.P. Botkin). Inclusion criteria for patients in the study were an adequate dialysis according to the KT/V index ≥1.4, absence of an active inflammatory process or infections, age over 18 years, standard hemodialysis regimen of 3 times per week, at least 4 h, levels of interleukin-6 (IL-6), IL-8, and C-reactive protein (CRP) above the reference values. Patients were transferred from hemodialysis performed using a standard polysulfone (PS) membrane to a polymethylmethacrylate (PMMA) membrane (Filtryzer BK-2.1F). For dialysis treatment in patients, blood flow rates of 250–350 mL/min were used, and the flow rate of the dialysis solution was set at 500 mL/min. The control group consisted of 19 patients, with similar inclusion parameters, who continued their treatment with hemodialysis using a PS membrane. The aim of the research was to study the effect of the dialysis membrane (Filtryzer BK-2.1F) on the level of inflammation in routine practice compared to a PS membrane. Adverse events were monitored. Results By the end of the study, after 12 months, the levels of cytokines significantly decreased only in patients who had treatment with PMMA membrane, starting from the 3rd month of treatment, and became close to normal levels: IL-6 from 16.9 ± 8.0 to 8.5 ± 4.8 pg/mL (p ≤ 0.0001); IL-8 from 78.5 ± 11.4 to 43.6 ± 11.6 pg/mL (p ≤ 0.0001); and CRP from 10.33 ± 2.83 to 6.15 ± 1.57 mg/L (p ≤ 0.0001). Values of inflammation markers did not change in control group. Conclusion In our study, we demonstrated for the first time a significant reduction in the level of inflammation in patients on standard hemodialysis in routine practice due to the use of PMMA membranes.